US Zulassung + Partnerschaft in 2010 = TOP PICK
Dieser Thread wurde 348 mal
gelesen
und wurde mit 2 Punkten bewertet
1 
US Zulassung + Partnerschaft in 2010 = TOP PICK
11.03.10 18:59
Biotechmaster
Wertpapier:
INTELLIPHARMACEUTICS INTL
Diese Aktie gehört wohl zu den günstigsten Biotechs überhaupt aber am besten macht eure Hausaufgaben selbst und ihr werdet staunen .
Hier hat man die Chance wirklich sehr gutes geld zu verdienen .
IntelliPharmaceutics (IPCI)
Marktkap: 17 Mio$
Cash: 8 Mio$
Kurs: 1,50 $
Shares Out: 10,9 M
Pipeline
http://www.intellipharmaceutics.com/pipeline.cfm
Präsentation März 2010
http://files.shareholder.com/downloads/...b7/Intellipharmaceutics.pdf
Intellipharmaceutics' development milestones for 2010 include the following:
-- Potential conclusion of the ongoing litigation process and/or FDA
approval of Focalin XR
-- File and have accepted for review by the FDA, two additional ANDA applications
-- Establish at least one additional development/marketing alliance
-- Complete successful manufacturing of clinical batches of Rexista(TM)
-- Complete Phase 1 studies using clinical batches of Rexista(TM)
-- Schedule a pre-IND meeting with FDA to discuss Rexista(TM) clinical
development plan
Hier hat man die Chance wirklich sehr gutes geld zu verdienen .
IntelliPharmaceutics (IPCI)
Marktkap: 17 Mio$
Cash: 8 Mio$
Kurs: 1,50 $
Shares Out: 10,9 M
Pipeline
http://www.intellipharmaceutics.com/pipeline.cfm
Präsentation März 2010
http://files.shareholder.com/downloads/...b7/Intellipharmaceutics.pdf
Intellipharmaceutics' development milestones for 2010 include the following:
-- Potential conclusion of the ongoing litigation process and/or FDA
approval of Focalin XR
-- File and have accepted for review by the FDA, two additional ANDA applications
-- Establish at least one additional development/marketing alliance
-- Complete successful manufacturing of clinical batches of Rexista(TM)
-- Complete Phase 1 studies using clinical batches of Rexista(TM)
-- Schedule a pre-IND meeting with FDA to discuss Rexista(TM) clinical
development plan
2 
beobachte ich mal, danke
11.03.10 19:04
Slater
Wertpapier:
INTELLIPHARMACEUTICS INTL
3 Super News Nachbörslich
12.03.10 10:19
Biotechmaster
Wertpapier:
INTELLIPHARMACEUTICS INTL
Die News bedeutet das der Weg für die Zulassung frei ist .. Meine Empfehlung lautet alles unter 2$ wegkaufen denn IPCI ist mit 17 Mio$ Marktkapitalisierung gnadenlos unterbewertet .
Viel Glück
Intellipharmaceutics Announces Settlement for its Generic Version of Focalin XR(R)
TORONTO, March 11, 2010 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. ( Nasdaq :IPCI) (TSX:I) today announced that Novartis Pharmaceuticals Corporation and Celgene Corporation have settled their patent suit in the U.S. District Court for the District of New Jersey, and Elan Pharma International Ltd. has settled its patent suit in the U.S. District Court for the District of Delaware, with Intellipharmaceutics Corp., a wholly-owned subsidiary of Intellipharmaceutics International, and its licensee Par Pharmaceutical, Inc. over a generic version of the Attention Deficit Hyperactivity Disorder drug Focalin XR® (dexmethylphenidate hydrochloride). The terms of the settlements are confidential and remain subject to regulatory and court approval.
Viel Glück
Intellipharmaceutics Announces Settlement for its Generic Version of Focalin XR(R)
TORONTO, March 11, 2010 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. ( Nasdaq :IPCI) (TSX:I) today announced that Novartis Pharmaceuticals Corporation and Celgene Corporation have settled their patent suit in the U.S. District Court for the District of New Jersey, and Elan Pharma International Ltd. has settled its patent suit in the U.S. District Court for the District of Delaware, with Intellipharmaceutics Corp., a wholly-owned subsidiary of Intellipharmaceutics International, and its licensee Par Pharmaceutical, Inc. over a generic version of the Attention Deficit Hyperactivity Disorder drug Focalin XR® (dexmethylphenidate hydrochloride). The terms of the settlements are confidential and remain subject to regulatory and court approval.
4 Letzte Chance unter 2$ zukaufen
12.03.10 17:41
Biotechmaster
Wertpapier:
INTELLIPHARMACEUTICS INTL
Verpasst die gelegenheit des Jahres nicht ...Die Aktie kann dieses Jahr noch über 10$ steigen .
Es bleibt natürlich eure Entscheidung .
Es bleibt natürlich eure Entscheidung .
5 Ralllyyyyyyyyyyyyyyyyyyy
12.03.10 18:06
Biotechmaster
Wertpapier:
INTELLIPHARMACEUTICS INTL
Marktkap ist immer noch ein Witz mit rund 22 Mio$...
http://ih.advfn.com/...hart&s=N%5EIPCI&p=0&t=19&vol=1
http://ih.advfn.com/...hart&s=N%5EIPCI&p=0&t=19&vol=1
6 IPCI explodiert gerade
12.03.10 19:35
Biotechmaster
Wertpapier:
INTELLIPHARMACEUTICS INTL
Und ist nach wie vor gnadenlos unterbewertet
http://ih.advfn.com/...hart&s=N%5EIPCI&p=0&t=19&vol=1
http://ih.advfn.com/...hart&s=N%5EIPCI&p=0&t=19&vol=1
7 Knapp 200% plus
12.03.10 20:07
Biotechmaster
Wertpapier:
INTELLIPHARMACEUTICS INTL
Geillllllllllllllllllllllllllllllll
8 
glückwunsch zum glücklichen Händchen
12.03.10 20:09
Benull
Wertpapier:
INTELLIPHARMACEUTICS INTL
9 Trotz Anstieg bleibt IPCI unterbewertet ....
14.03.10 19:38
Biotechmaster
Wertpapier:
INTELLIPHARMACEUTICS INTL
100-200% sind immer locker möglich ...
IntelliPharmaceutics (IPCI)
Marktkap: 44 Mio$
Cash: 8 Mio$
Kurs: 4,14 $
Shares Out: 10,9 M ( CEO hält 6 Mio Aktien )
Präsentation März 2010
http://files.shareholder.com/downloads/...b7/Intellipharmaceutics.pdf
Pipeline
http://www.intellipharmaceutics.com/pipeline.cfm
CEO hält 6 Million Aktien ...
http://secfilings.nasdaq.com/...D&RcvdDate=11%2F2%2F2009&pdf=
Intellipharmaceutics' development milestones for 2010 include the following:
-- Potential conclusion of the ongoing litigation process and/or FDA
approval of Focalin XR
-- File and have accepted for review by the FDA, two additional ANDA applications
-- Establish at least one additional development/marketing alliance
-- Complete successful manufacturing of clinical batches of Rexista(TM)
-- Complete Phase 1 studies using clinical batches of Rexista(TM)
-- Schedule a pre-IND meeting with FDA to discuss Rexista(TM) clinical
development plan
Par Pharma (PRX) ist Zweitgrößter Aktionär ...
IPC's shareholders are expected to own approximately 86% of the outstanding common shares of the combined company and Vasogen's shareholders are expected to own approximately 14% of the outstanding common shares. IPC and Vasogen are currently assessing the appropriate capital structure for the combined company moving forward, which will take into consideration of a number of factors, including input from discussions with NASDAQ and the TSX. Following this assessment, IPC and Vasogen plan to outline their proposal and plans in a joint proxy circular to be provided to shareholders, which is expected to be filed in the coming weeks. Dr. Isa Odidi and Dr. Amina Odidi would together beneficially own approximately 55.3% of the combined company. IPC's second largest shareholder, Par Pharmaceutical, which acquired an equity interest in IPC in 2007 at the same time as it entered into a product commercialization agreement with IPC for the development and commercialization of four product candidates, would effectively own approximately 3.6% of the combined company after closing. The combined company will retain ownership of Vasogen's intellectual property; however, the development focus is expected to be principally on IPC's current product pipeline.
IntelliPharmaceutics (IPCI)
Marktkap: 44 Mio$
Cash: 8 Mio$
Kurs: 4,14 $
Shares Out: 10,9 M ( CEO hält 6 Mio Aktien )
Präsentation März 2010
http://files.shareholder.com/downloads/...b7/Intellipharmaceutics.pdf
Pipeline
http://www.intellipharmaceutics.com/pipeline.cfm
CEO hält 6 Million Aktien ...
http://secfilings.nasdaq.com/...D&RcvdDate=11%2F2%2F2009&pdf=
Intellipharmaceutics' development milestones for 2010 include the following:
-- Potential conclusion of the ongoing litigation process and/or FDA
approval of Focalin XR
-- File and have accepted for review by the FDA, two additional ANDA applications
-- Establish at least one additional development/marketing alliance
-- Complete successful manufacturing of clinical batches of Rexista(TM)
-- Complete Phase 1 studies using clinical batches of Rexista(TM)
-- Schedule a pre-IND meeting with FDA to discuss Rexista(TM) clinical
development plan
Par Pharma (PRX) ist Zweitgrößter Aktionär ...
IPC's shareholders are expected to own approximately 86% of the outstanding common shares of the combined company and Vasogen's shareholders are expected to own approximately 14% of the outstanding common shares. IPC and Vasogen are currently assessing the appropriate capital structure for the combined company moving forward, which will take into consideration of a number of factors, including input from discussions with NASDAQ and the TSX. Following this assessment, IPC and Vasogen plan to outline their proposal and plans in a joint proxy circular to be provided to shareholders, which is expected to be filed in the coming weeks. Dr. Isa Odidi and Dr. Amina Odidi would together beneficially own approximately 55.3% of the combined company. IPC's second largest shareholder, Par Pharmaceutical, which acquired an equity interest in IPC in 2007 at the same time as it entered into a product commercialization agreement with IPC for the development and commercialization of four product candidates, would effectively own approximately 3.6% of the combined company after closing. The combined company will retain ownership of Vasogen's intellectual property; however, the development focus is expected to be principally on IPC's current product pipeline.
